Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria for Double Blinded Phase:~* Histologically or cytologically confirmed adenocarcinoma of the breast;~* Female subjects with non-metastatic disease who are estrogen receptor (ER) and/or progesterone receptor (PR) positive, and who have completed their treatment pathway;~* Subjects who are currently on, or will initiate an approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting;~* Postmenopausal woman, defined as a woman fulfilling any one of the following criteria:~  * Having undergone a bilateral oophorectomy;~ * Age ≥ 60 years;~ * Aged \< 60 years meeting the following requirements:~* Follicle-stimulating hormone (FSH) and estradiol in the postmenopausal range;~* A negative pregnancy test within 7 days prior to randomization. Subjects who have undergone a hysterectomy do not require a pregnancy test.~* More criteria may apply.~Exclusion Criteria for Double Blinded Phase:~* Aromatase inhibitor therapy for more than 24 months;~* Prior or concurrent treatment with Selective Estrogen Receptor Modulators (eg, tamoxifen);~* Evidence of metastatic disease;~* Current or prior intravenous (IV) bisphosphonate administration;~* Oral bisphosphonate treatment greater than or equal to 3 years continuously OR greater than 3 months but less than 3 years unless there was a washout period of at least 1 year prior to randomization OR any use during the 3-month period prior to randomization;~* Prior administration of denosumab;~* Known liver or renal deficiency;~* Recurrence of the primary malignancy (e.g., during the allowed interval of pretreatment with aromatase inhibitor);~* Diagnosis of any second non-breast malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri;~* Any kind of disorder that compromises the ability to give written informed consent and/or comply with study procedures.~Inclusion Criteria to Receive Open-label Phase Denosumab:~* Obtain signed and dated written informed consent prior to performing any study-specific procedure;~* Subjects currently taking an approved non-steroidal AIT (eg, anastrazole) or who have completed or discontinued AIT within 12 months prior to participation in the OLP;~* Randomized to placebo arm during the double-blind phase (as determined by unblinding procedures);~Exclusion Criteria to Receive Open-label Phase Denosumab:~* Current or prior IV bisphosphonate administration;~* Subjects meeting the following criteria for oral bisphosphonate treatment:~  * Greater than or equal to 3 years continuously,~ * Greater than 3 months but less than 3 years unless subject has had a washout period of at least 1 year prior to participation in the OLP,~ * Any use during the 3-month period prior to participation in the OLP;~* Prior or concurrent treatment with SERMs (eg, tamoxifen);~* Subjects who ended treatment with investigational product (IP) prematurely in the double-blind phase; Treatment with commercial denosumab (Prolia or Xgeva) prior to participation in the OLP.~Eligibility for ZA substudy Inclusion Criteria~* Obtain signed and dated written informed consent prior to performing any substudy-specific procedure~* Subjects that received OLP denosumab and completed OLP treatment~* Last OLP denosumab administration no longer than 9 months ago Exclusion Criteria~* Current or prior ZA administration.~* Subjects who ended treatment with investigational product (IP) prematurely in the double-blind phase and OL phase~* Known sensitivity or intolerance to any of the products to be administered during the substudy (eg, ZA, calcium or vitamin D)~* Known history of any of the following conditions either by subject self report or chart review~  * Paget's disease (bone), Cushing's disease, hyperprolactinemia or other active metabolic bone disease~ * Known history of hypocalcemia~ * Major surgery, or significant traumatic injury occurring within 4 weeks prior to randomization~ * Parathyroid glands in neck surgically removed.~ * Any sections of intestine removed.~ * Known human immunodeficiency virus infection~ * Active infection with hepatitis B or hepatitis C virus~* Known liver or renal disease as determined by the investigator and indicated by the following criteria:~  * Aspartate aminotransferase ≥ 2.5 x ULN~ * Alanine transaminase ≥ 2.5 x ULN~ * Serum creatinine ≥ 2 x ULN~ * Creatine clearance \< 35ml/min Subjects that are pregnant or breastfeeding~ * All subjects with reproductive potential must have a negative pregnancy test within 7 days before randomization~* Subjects who are osteoporotic in baseline BMD

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: EXPERIMENTAL): Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
- SubStudy: Zoledronic Acid (Type: EXPERIMENTAL): Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive a single 5 mg intravenous dose of zoledronic acid 8 months after the last open-label dose of denosumab.
- Substudy: Standard of Care (Type: OTHER): Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive standard of care 8 months after the last open-label dose of denosumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).